Campbell & CO Investment Adviser LLC Invests $274,000 in ACADIA Pharmaceuticals Inc. (ACAD)

Campbell & CO Investment Adviser LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,817 shares of the biopharmaceutical company’s stock, valued at approximately $274,000.

A number of other hedge funds have also modified their holdings of the company. Stifel Financial Corp raised its position in ACADIA Pharmaceuticals by 3.1% in the first quarter. Stifel Financial Corp now owns 8,708 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares in the last quarter. Nisa Investment Advisors LLC raised its position in ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 510 shares in the last quarter. Envestnet Asset Management Inc. raised its position in ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 617 shares in the last quarter. Creative Planning raised its position in ACADIA Pharmaceuticals by 4.9% in the second quarter. Creative Planning now owns 24,915 shares of the biopharmaceutical company’s stock worth $695,000 after buying an additional 1,159 shares in the last quarter. Finally, Geneva Advisors LLC raised its position in ACADIA Pharmaceuticals by 8.4% in the first quarter. Geneva Advisors LLC now owns 18,002 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 1,396 shares in the last quarter. Hedge funds and other institutional investors own 97.82% of the company’s stock.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) opened at 31.08 on Friday. The stock has a 50 day moving average of $29.77 and a 200 day moving average of $32.03. ACADIA Pharmaceuticals Inc. has a 12-month low of $20.68 and a 12-month high of $40.83. The firm’s market cap is $3.80 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.17. The firm had revenue of $30.50 million for the quarter, compared to the consensus estimate of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The company’s revenue for the quarter was up 30400.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.63) EPS. On average, equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.55) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Campbell & CO Investment Adviser LLC Invests $274,000 in ACADIA Pharmaceuticals Inc. (ACAD)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/19/campbell-co-investment-adviser-llc-takes-position-in-acadia-pharmaceuticals-inc-acad-updated-updated.html.

ACAD has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, May 10th. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Tuesday, July 11th. BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Rodman & Renshaw restated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 22nd. Finally, ValuEngine raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $43.23.

In other news, EVP Glenn Baity sold 14,322 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $34.88, for a total transaction of $499,551.36. Following the transaction, the executive vice president now owns 78,578 shares of the company’s stock, valued at approximately $2,740,800.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 54,322 shares of company stock worth $1,699,551. Corporate insiders own 22.25% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

What are top analysts saying about ACADIA Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ACADIA Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit